Timmerman: Biotech success demands guts

With the odds stacked against them, intrepid biotech entrepreneurs have weathered the risky nature of drug development for decades in hopes of having an unlikely success. In these troubled financial times, however, Xconomy's Luke Timmerman writes today that developers need to keep their nerve to maintain their edge in this difficult industry. Indeed, behind some of the industry's successful drugs are those who wanted to quit on the drugs during development and those who championed further testing of the treatments. Column

Suggested Articles

No biohazardous substances were in the room where the explosion happened, according to the Russian virology center.

Merck has a shot at becoming the first company to receive clearance to sell a vaccine against the virus in the U.S.

Acceleron has chalked up another phase 2 flop as its pipeline thins a little more.